Gyre Therapeutics, Inc. (GYRE)
6.71
+0.02
(+0.30%)
USD |
NASDAQ |
Sep 16, 14:07
Gyre Therapeutics Enterprise Value : 694.98M for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 694.98M |
| September 14, 2026 | 694.98M |
| September 11, 2026 | 699.22M |
| September 10, 2026 | 700.28M |
| September 09, 2026 | 722.55M |
| September 08, 2026 | 745.88M |
| September 04, 2026 | 713.00M |
| September 03, 2026 | 668.47M |
| September 02, 2026 | 659.99M |
| September 01, 2026 | 671.65M |
| August 31, 2026 | 682.26M |
| August 28, 2026 | 684.38M |
| August 27, 2026 | 693.92M |
| August 26, 2026 | 690.74M |
| August 25, 2026 | 693.92M |
| August 24, 2026 | 668.47M |
| August 21, 2026 | 718.31M |
| August 20, 2026 | 729.97M |
| August 19, 2026 | 743.75M |
| August 18, 2026 | 725.73M |
| August 17, 2026 | 707.70M |
| August 14, 2026 | 693.92M |
| August 13, 2026 | 679.07M |
| August 12, 2026 | 691.80M |
| August 11, 2026 | 689.68M |
| Date | Value |
|---|---|
| August 10, 2026 | 698.16M |
| August 07, 2026 | 692.86M |
| August 06, 2026 | 664.23M |
| August 05, 2026 | 646.20M |
| August 04, 2026 | 637.72M |
| August 03, 2026 | 633.48M |
| July 31, 2026 | 595.31M |
| July 30, 2026 | 601.67M |
| July 29, 2026 | 583.64M |
| July 28, 2026 | 620.76M |
| July 27, 2026 | 635.60M |
| July 24, 2026 | 615.45M |
| July 23, 2026 | 622.88M |
| July 22, 2026 | 615.45M |
| July 21, 2026 | 628.18M |
| July 20, 2026 | 609.09M |
| July 17, 2026 | 627.12M |
| July 16, 2026 | 666.35M |
| July 15, 2026 | 681.19M |
| July 14, 2026 | 657.87M |
| July 13, 2026 | 657.87M |
| July 10, 2026 | 676.95M |
| July 09, 2026 | 713.00M |
| July 08, 2026 | 713.00M |
| July 07, 2026 | 728.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cytokinetics, Inc. | 9.719B |
| ACADIA Pharmaceuticals, Inc. | 3.724B |
| Alnylam Pharmaceuticals, Inc. | 31.54B |
| Anika Therapeutics, Inc. | 266.68M |
| Savara, Inc. | 937.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.27M |
| Revenue (Quarterly) | 29.10M |
| Total Expenses (Quarterly) | 39.71M |
| EPS Diluted (Quarterly) | -0.1159 |
| Gross Profit Margin (Quarterly) | 92.41% |
| Profit Margin (Quarterly) | -49.03% |
| Earnings Yield | -2.92% |
| Normalized Earnings Yield | -2.629 |